|
[1]
|
Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial
Antimicrobial Agents and Chemotherapy,
2024
DOI:10.1128/aac.00778-23
|
|
|
|
|
[2]
|
Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306
Journal of Women's Health,
2023
DOI:10.1089/jwh.2022.0132
|
|
|
|
|
[3]
|
Characterization and susceptibility of non-albicans Candida isolated from various clinical specimens in Lebanese hospitals
Frontiers in Public Health,
2023
DOI:10.3389/fpubh.2023.1115055
|
|
|
|
|
[4]
|
Modern concepts of etiopathogenesis and approaches to the treatment of recurrent vulvovaginal candidiasis
Vestnik dermatologii i venerologii,
2023
DOI:10.25208/vdv11879
|
|
|
|
|
[5]
|
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis
Clinical Infectious Diseases,
2022
DOI:10.1093/cid/ciab841
|
|
|
|
|
[6]
|
Simulated Vaginal Fluid: Candida resistant strains’ biofilm characterization and vapor phase of essential oil effect
Journal of Medical Mycology,
2022
DOI:10.1016/j.mycmed.2022.101329
|
|
|
|
|
[7]
|
Microbiological study of vaginitis among women of reproductive age group
IP International Journal of Medical Microbiology and Tropical Diseases,
2022
DOI:10.18231/j.ijmmtd.2022.045
|
|
|
|
|
[8]
|
Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306
Journal of Women's Health,
2022
DOI:10.1089/jwh.2022.0132
|
|
|
|
|
[9]
|
In Vitro
pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant
Candida
Isolates from Women with Vulvovaginal Candidiasis
Antimicrobial Agents and Chemotherapy,
2021
DOI:10.1128/AAC.00562-21
|
|
|
|
|
[10]
|
Update Vaginalmykose
Der Gynäkologe,
2020
DOI:10.1007/s00129-020-04664-6
|
|
|
|
|
[11]
|
Investigating the Frequency of Candida glabrata in Diabetic Women of Tehran with Recurrent and Non-recurrent Vulvovaginal Candidiasis Using PCR-RFLP Assay
Journal of Medical Microbiology and Infectious Diseases ,
2019
DOI:10.29252/JoMMID.7.1.2.44
|
|
|
|
|
[12]
|
Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment
Antimicrobial Agents and Chemotherapy,
2019
DOI:10.1128/AAC.02690-18
|
|
|
|
|
[13]
|
Recurrent vulvo-vaginal candidiasis in Abidjan (Côte d’Ivoire): Aetiology and associated factors
Journal de Mycologie Médicale,
2019
DOI:10.1016/j.mycmed.2019.04.002
|
|
|
|
|
[14]
|
Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species
Infectious Diseases in Obstetrics and Gynecology,
2018
DOI:10.1155/2018/7040498
|
|
|
|
|
[15]
|
Is multiple-site colonization with Candida spp. related to inadequate response to individualized fluconazole maintenance therapy in women with recurrent Candida vulvovaginitis?
Diagnostic Microbiology and Infectious Disease,
2018
DOI:10.1016/j.diagmicrobio.2018.05.024
|
|
|
|
|
[16]
|
Identification of Candida Species Isolated from Vulvovaginal Candidiasis Patients by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) in Yasuj Southwestern Iran
Jundishapur Journal of Microbiology,
2018
DOI:10.5812/jjm.65359
|
|
|
|
|
[17]
|
Candida africana in recurrent vulvovaginal candidiasis (RVVC) patients: frequency and phenotypic and genotypic characteristics
Journal of Medical Microbiology,
2018
DOI:10.1099/jmm.0.000834
|
|
|
|
|
[18]
|
An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis
Journal of Fungi,
2018
DOI:10.3390/jof4040121
|
|
|
|
|
[19]
|
Candida and its dual lifestyle as a commensal and a pathogen
Research in Microbiology,
2017
DOI:10.1016/j.resmic.2017.02.005
|
|
|
|